Cannara Biotech (LOVFF)
OTHER OTC:LOVFF
LOVFF Stock Chart & Stats
$1.32
<$0.01(1.07%)
At close: 4:00 PM EST
$1.32
<$0.01(1.07%)
Day’s Range― - ―
52-Week Range$0.81 - $1.47
Previous CloseN/A
Volume3.00K
Average Volume (3M)2.46K
Market Cap
$137.52M
Enterprise Value$203.20M
Total Cash (Recent Filing)$16.52M
Total Debt (Recent Filing)$34.85M
Price to Earnings (P/E)37.0
Beta0.42
Next Earnings
Apr 14, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding98,782,150
10 Day Avg. Volume4,074
30 Day Avg. Volume2,464
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.64
Price to Sales (P/S)1.57
P/FCF Ratio12.31
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit4.67
Enterprise Value/Ebitda7.51
Forecast
1Y Price Target
$2.23Price Target Upside68.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.11
Revenue Forecast (FY)$91.82M
Bulls Say, Bears Say
Bulls Say
Strong Profit MarginsSustained high gross and operating margins indicate a structurally profitable manufacturing and go-to-market model in the regulated cannabis channel. These margins provide durable cash cushion to absorb cost shocks, fund product development, and sustain investment in brand and distribution over months.
Improving Leverage And ReturnsDeclining leverage alongside healthy return on equity reflects improving capital structure and financial discipline. Lower leverage over time reduces interest burden and refinancing exposure, increasing strategic flexibility to fund growth or withstand industry cyclicality over the medium term.
Positive Operating Cash GenerationConsistent operating cash flow and positive free cash flow demonstrate the business can convert earnings into internally available capital. This supports reinvestment in cultivation and processing capacity, reduces reliance on external financing, and underpins sustainable operations over coming quarters.
Bears Say
Volatile Free Cash FlowMeasured FCF decline and prior periods of negative FCF point to uneven cash conversion from operations. Persistent volatility can hinder consistent capex, slow product rollout or require external funding, raising execution risk and constraining strategic initiatives over a multi-month horizon.
Earnings Normalization RiskA decline versus the prior annual peak suggests earnings may be reverting after a strong year. If persistent, this could reflect market saturation, pricing pressure, or rising costs, reducing internal funding capacity and making it harder to sustainably expand margins or invest in growth.
Meaningful Absolute Debt LevelEven with improving leverage ratios, a material absolute debt load increases sensitivity to cashflow downturns or rising rates. Debt servicing can limit capital allocation flexibility and elevate refinancing risk if industry demand softens or margins compress over the medium term.
Cannara Biotech News
LOVFF FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was $0.81 and its highest was $1.47 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is $137.52M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Apr 14, 2026 which is tomorrow.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Jan 26, 2026. The company reported $0.007 earnings per share for the quarter, beating the consensus estimate of N/A by $0.007.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.04.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of $0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.21%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in LOVFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannara Biotech
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
LOVFF Company Deck
LOVFF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record-breaking metrics and significant market share growth in key regions and product categories. However, there are challenges in maintaining market share in certain regions and managing cash flow effectively.View all LOVFF earnings summariesLOVFF Stock 12 Month Forecast
Average Price Target
$2.23
▲(68.76% Upside)
Technical Analysis
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
Cannabist Company Holdings
―
Grown Rogue International
―
Ownership Overview
Options Prices
Currently, No data available
---